We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Changes EUA So Olumiant Can Stand Alone in Treating COVID-19
FDA Changes EUA So Olumiant Can Stand Alone in Treating COVID-19
The FDA has revised its Emergency Use Authorization (EUA) for Eli Lilly’s and Incyte’s COVID-19 treatment Olumiant (baricitinib) to authorize giving the drug alone for the treatment of COVID-19 in hospitalized adults and pediatric patients two years or older requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.